Susceptibility genes for the development of SLE during treatment of IBD
A potential and very serious side effect of treating IBD with antiTNFa therapies (the currentgold standard) is the development of systemic lupus erythematosis (SLE). This side effect israre and unpredictable. Out of several thousand cases having received treatment, theUniversity of Calgary have accumulated 12 individuals with full phenotyping and novelserological antibody discovery panel data. We propose to exome sequence these samples inan effort to identify rare highly-penetrant variants that could be underlying this severephenotype.
- 27/05/2015
- 15 samples
- DAC: EGAC00001000111
- Technology: Illumina HiSeq 2000
Wellcome Trust Sanger Institute Data Sharing Policy
The data will be submitted to EGA and are accessible under managed data access.https://www.sanger.ac.uk/datasharing/
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
| Study ID | Study Title | Study Type |
|---|---|---|
| EGAS00001000387 | Other |
This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.